Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality.

Casulli J, Fife ME, Houston SA, Rossi S, Dow J, Williamson ED, Clark GC, Hussell T, D'Elia RV, Travis MA.

Nat Commun. 2019 May 9;10(1):2121. doi: 10.1038/s41467-019-10156-6.

2.

Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments.

D'Elia RV, Woods S, Butcher W, McGahon J, Khadke S, Perrie Y, Williamson ED, Roberts CW.

J Control Release. 2019 Mar 28;298:202-212. doi: 10.1016/j.jconrel.2019.02.002. Epub 2019 Feb 4.

3.

Histopathological and immunohistochemical characterization of Burkholderia pseudomallei lesions in an acute model of infection with BALB/c mice.

García-Jiménez WL, Salguero FJ, D'Elia RV.

Int J Exp Pathol. 2017 Dec;98(6):347-355. doi: 10.1111/iep.12258. Epub 2018 Jan 7.

4.

Mitogen-activated protein kinases (MAPKs) are modulated during in vitro and in vivo infection with the intracellular bacterium Burkholderia pseudomallei.

D'Elia RV, Saint RJ, Newstead SL, Clark GC, Atkins HS.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2147-2154. doi: 10.1007/s10096-017-3038-0. Epub 2017 Aug 30.

5.

Current and future developments in the treatment of virus-induced hypercytokinemia.

Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV.

Future Med Chem. 2017 Feb;9(2):169-178. doi: 10.4155/fmc-2016-0181. Epub 2017 Jan 27. Review.

PMID:
28128003
6.
7.

Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1.

Laws TR, Clark GC, D'Elia RV.

Int J Infect Dis. 2015 Nov;40:1-8. doi: 10.1016/j.ijid.2015.09.003. Epub 2015 Sep 7.

8.

"FoxP3 Hunting" during infection with Francisella tularensis.

D'Elia RV, Laws TR, Núñez A, Clark GC.

Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):585-95. doi: 10.1177/039463201402700414.

PMID:
25572738
9.

Delayed presence of alternatively activated macrophages during a Francisella tularensis infection.

D'Elia RV, Laws TR, Núñez A, Taylor C, Clark GC.

Microb Pathog. 2015 Jan;78:37-42. doi: 10.1016/j.micpath.2014.10.002. Epub 2014 Oct 2.

PMID:
25284816
10.

Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.

Scott AE, Ngugi SA, Laws TR, Corser D, Lonsdale CL, D'Elia RV, Titball RW, Williamson ED, Atkins TP, Prior JL.

J Immunol Res. 2014;2014:392170. doi: 10.1155/2014/392170. Epub 2014 May 7.

11.

Targeting the "Rising DAMP" during a Francisella tularensis Infection.

D'Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24.

12.

Differential role for interleukin-6 during Francisella tularensis infection with virulent and vaccine strains.

Laws TR, Clark G, D'Elia RV.

Infect Immun. 2013 Aug;81(8):3055-6. doi: 10.1128/IAI.00234-13. Epub 2013 May 28. No abstract available.

13.

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, Williamson D, Atkins TP, Prior JL, Wren BW.

Open Biol. 2013 May 22;3(5):130002. doi: 10.1098/rsob.130002.

14.

Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Scott AE, Laws TR, D'Elia RV, Stokes MG, Nandi T, Williamson ED, Tan P, Prior JL, Atkins TP.

Clin Vaccine Immunol. 2013 Jul;20(7):1041-7. doi: 10.1128/CVI.00113-13. Epub 2013 May 15.

15.

Targeting the "cytokine storm" for therapeutic benefit.

D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC.

Clin Vaccine Immunol. 2013 Mar;20(3):319-27. doi: 10.1128/CVI.00636-12. Epub 2013 Jan 2. Review.

16.

A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus.

Goodchild SA, O'Brien LM, Steven J, Muller MR, Lanning OJ, Logue CH, D'Elia RV, Phillpotts RJ, Perkins SD.

Antiviral Res. 2011 Apr;90(1):1-8. doi: 10.1016/j.antiviral.2011.01.010. Epub 2011 Feb 15.

PMID:
21310183

Supplemental Content

Loading ...
Support Center